CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers that offer a benefit to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma. It is also engaged in evaluating pacritinib for the treatment of adult patients with myelofibrosis. CTI BioPharma's earlier stage product candidate, tosedostat, is an oral, once-daily aminopeptidase inhibitor that has demonstrated responses in patients with acute myeloid leukemia. It also evaluates its pipeline candidate paclitaxel poliglumex, which targets solid tumors.

Type
Public
HQ
Seattle, US
Founded
1992
Size (employees)
100 (est)
CTI BioPharma was founded in 1992 and is headquartered in Seattle, US
Report incorrect company information

CTI BioPharma Office Locations

CTI BioPharma has an office in Seattle
Seattle, US (HQ)
600 3101 Western Ave
Show all (1)
Report incorrect company information

CTI BioPharma Financials and Metrics

CTI BioPharma Financials

CTI BioPharma's revenue was reported to be $25.15 m in FY, 2017
USD

Revenue (FY, 2017)

25.1 m

Net income (FY, 2017)

(45 m)

EBIT (FY, 2017)

(39.5 m)

Market capitalization (18-Apr-2018)

139.3 m

Cash (31-Dec-2017)

27.2 m

EV

112.6 m
CTI BioPharma's current market capitalization is $139.3 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

34.7 m60.1 m16.1 m57.4 m25.1 m

Revenue growth, %

73%(73%)256%

Cost of goods sold

137 k895 k1.9 m1.4 m

Gross profit

34.5 m59.2 m14.2 m56 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

362 k1.4 m1.3 m39.5 m2.7 m1.1 m964 k36.5 m7.4 m4.4 m754 k22.2 m

General and administrative expense

8.5 m16.8 m13.8 m12.6 m12.3 m12.6 m13.7 m11.3 m9.6 m15.2 m10.7 m8 m

R&D expense

7.2 m12.2 m14 m16.5 m17.5 m19.3 m18.4 m20.8 m16.7 m17.7 m9.3 m8.9 m

Operating expense total

15.9 m29.1 m28 m32.1 m30.2 m32.1 m32.9 m32.3 m26.4 m33.1 m20.1 m17 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

71.6 m70.9 m128.2 m44 m27.2 m

Accounts Receivable

235 k2 m282 k378 k4 k

Inventories

3.6 m3.4 m3.7 m1.5 m550 k

Current Assets

80.5 m80.5 m135 m55.8 m46.9 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

27.2 m50.6 m33.2 m29.9 m44.4 m54.9 m46.4 m104.6 m76.7 m61.6 m33.3 m74.7 m

Accounts Receivable

540 k503 k613 k1.2 m1.3 m880 k422 k666 k559 k620 k311 k480 k

Inventories

3.7 m5 m5 m4.5 m3.6 m3.6 m2.6 m2.9 m2.6 m2.6 m1.5 m1.5 m

Current Assets

33.7 m59.9 m42.3 m55.9 m53.5 m63.9 m53.3 m113.9 m88.9 m67.9 m36.8 m78.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(43.6 m)(94.2 m)(120.8 m)(53 m)

Depreciation and Amortization

1.6 m1.1 m990 k831 k717 k

Inventories

4.5 m46 k(402 k)567 k1.1 m

Accounts Payable

(5.8 m)1.5 m4.4 m(3 m)(4.7 m)
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(29 m)(27.4 m)(28.6 m)(32.6 m)(32.6 m)3.3 m(19.8 m)(29.2 m)(19.8 m)

Inventories

5 m4.5 m3.6 m3.6 m

Accounts Payable

6.4 m6.3 m10.3 m11.2 m13.4 m17.7 m14 m13.7 m11.9 m
USDY, 2017

EV/EBIT

-2.8 x

EV/CFO

-2.9 x

Revenue/Employee

251.5 k

Financial Leverage

3.4 x
Show all financial metrics

CTI BioPharma Operating Metrics

FY, 2016

Phase III Trials Products

2
Show all operating metrics
Report incorrect company information

CTI BioPharma News and Updates

Report incorrect company information